United Therapeutics CORP Form 4 insider transactions

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales of common stock under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on May 7, 2024, under a pre-arranged 10b5-1 trading plan.

Michael Benkowitz, COO of United Therapeutics, exercised share tracking awards and disposed of common stock on May 6, 2024.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on May 3rd and 6th, 2024, under a pre-arranged 10b5-1 trading plan.

Director Christopher Causey exercised stock options and sold shares of United Therapeutics Corp on May 3, 2024.

Director Judy D. Olian exercised stock options and sold shares of United Therapeutics Corp (UTHR) on May 3, 2024.

Director Louis W. Sullivan exercised stock options and sold shares of United Therapeutics Corp on May 3, 2024.

Martine Rothblatt, CEO of United Therapeutics, executed stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, CEO of United Therapeutics, executed stock option exercises and sales under a pre-arranged 10b5-1 trading plan on April 29 and 30, 2024.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on April 25 and 26, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on April 23 and 24, 2024, under a pre-arranged 10b5-1 trading plan.

Director Raymond Dwek exercised share tracking awards of United Therapeutics Corporation under a pre-arranged Rule 10b5-1 trading plan, resulting in cash settlement.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on April 17 and 18, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on April 15 and 16, 2024, under a pre-arranged 10b5-1 trading plan.

Director Raymond Dwek exercised share tracking awards of United Therapeutics Corporation under a pre-arranged Rule 10b5-1 trading plan.

Martine Rothblatt, CEO of United Therapeutics, executed stock option exercises and sales on April 11 and 12, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales under a pre-arranged 10b5-1 trading plan on April 9 and 10, 2024.

Director Raymond Dwek executed share tracking awards and disposed of common stock of United Therapeutics Corp on April 8, 2024, according to a Form 4 filing.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on April 5th and 8th, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, CEO of United Therapeutics, executed stock option exercises and sales on April 3rd and 4th, 2024, under a pre-arranged 10b5-1 trading plan.

Paul Mahon, EVP & General Counsel of United Therapeutics, exercised stock options and sold shares of common stock on April 4, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on April 1st and 2nd, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on March 27 and 28, 2024, under a pre-arranged 10b5-1 trading plan.

Nilda Mesa, a director at United Therapeutics Corp, sold 325 shares of common stock on March 27, 2024, at a price of $237.8 per share.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed multiple sales of common stock on March 25 and 26, 2024, through a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on March 21 and 22, 2024, under a pre-arranged 10b5-1 trading plan.

Paul A. Mahon, EVP & General Counsel of United Therapeutics, exercised stock options and sold shares of common stock on March 21, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Martine Rothblatt, CEO of United Therapeutics, executed stock option exercises and sales on March 19 and 20, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, CEO of United Therapeutics, executed stock option exercises and sales on March 15 and 18, 2024, under a pre-arranged 10b5-1 trading plan.